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ABSTRACT 
Breast cancer is one of the most common malignancies in women. It continues to 
be a major burden and cause of death among women worldwide. Molecular oncology is 
now one of the most promising fields that may contribute considerably to diagnosis of 
breast cancer and its metastases addressing major problems with early detection, accurate 
staging, and monitoring of breast cancer patients. The overall objective of these 
feasibility studies was to contribute to improved diagnosis, prognosis, and prediction of 
breast cancer disease through the development of reagents and protocols for the use of 
molecular biological advances and the assessment of the relative potential of these 
diagnostic procedures for the detection and quantification of multiple specific mRNA 
tumor markers. Newest molecular technologies such as real-time quantitative TaqMan 
RT-PCR assays, microarray analyses, and production of “in-house” arrays were included 
in the study. Tissue, blood, and bone marrow samples were obtained from surgeries of 
confirmed and suspected breast cancer patients. TaqMan assays were performed for six 
mRNA markers: MAGE 3, HER2/NEU, MGB 1, CK 20, PSA, and HPR. Low-density 
nylon arrays with 265 immobilized genes included in cell to cell interactions were used 
for microarray analyses. Three highly overexpressed genes from microarray analyses and 
negative controls were selected for custom spotting on nylon membranes to produce “in-
house” arrays. It was concluded that TaqMan assays can be easily designed and 
implemented for the screening of a large number of clinical specimens when including 
carefully selected controls, high purity RNA from samples, and a set of mRNA markers. 
Custom arrays can be produced incorporating multiple selected mRNA markers. It is 
suggested that the initial screening of biological samples could be done by microarray 
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analyses and individual positive samples could be confirmed by additional tests using 
real-time quantitative TaqMan assays. 
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     INTRODUCTION 
Breast cancer is the formation of a malignant tumor that has developed from cells 
in the breast.  
Breast Cancer Current Statistics 
Breast cancer continues to be one of the most common cancers and a major cause 
of death among women worldwide. According to the current statistics of the Centers for 
Disease Control and Prevention, breast cancer is the most common cancer in women in the 
United States (excluding skin cancer) accounting for 32 percent of all female cancers. 
Breast cancer is responsible for 18 percent of cancer deaths in women and is second only 
to lung cancer. The National Cancer Institute estimates that about 1 in 8 women in the 
United States (approximately 13.3 percent) will develop breast cancer during her lifetime. 
This estimate is based on cancer rates from 1997 through 1999 (1). The American Cancer 
Society estimates that in 2003 approximately 211,300 new invasive cases of breast cancer 
will be diagnosed among women in the United States (3,800 of those cases will be 
diagnosed in Louisiana). An estimated 39,800 women will die from breast cancer (700 
women will die in Louisiana). It is estimated that 1,300 men will be diagnosed and 400 
men will die of breast cancer during 2003 (2). 
Breast Cancer Types 
Each breast has 15 to 20 sections called lobes, which have many smaller sections 
called lobules. The lobes and lobules are connected by thin tubes, called ducts (Figure1). 
The most common type of breast cancer is ductal cancer. It is found in the cells of the 
ducts. Cancer that starts in lobes or lobules is called lobular cancer. It is more often found 
in both breasts than other types of breast cancer. Cancers also are classified as non-
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invasive (in situ) and invasive (infiltrating). The term in situ refers to cancer that has not 
spread past the area where it initially developed. Invasive breast cancer has a tendency to 
spread (metastasize) to other tissues of the breast and/or other regions of the body. A less 
common type of breast cancer is inflammatory breast cancer characterized by general 
inflammation of the breast. Other rare types of breast cancer are medullary carcinoma (an 
invasive breast cancer that forms a distinct boundary between tumor tissue and normal 
tissue), mucinous carcinoma (formed by the mucus-producing cancer cells), tubular 
carcinoma, etc. (3).   
              
       
       Figure 1: The structure of the female breast 
      
Historical Overview 
While the incidence of breast cancer as well as the recovery rate continues to rise, 
breast cancer is hardly a new affliction (4-8). The recorded history of breast cancer traces 
back thousands of years. It is no surprise that from the dawn of history doctors have 
written about cancer. Incidents of breast cancer have been documented back to the early 
Egyptians when the popular treatment was cautery of the diseased tissue. Surgery was 
practiced but it was an extremely radical treatment considering there was no anesthesia or 
antisepsis available.  
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The oldest description of cancer (although the term cancer was not used) was 
discovered in Egypt and dates back to approximately 1600 B.C. The Edwin Smith Papyrus 
describes 8 cases of tumors or ulcers of the breast that were treated by cauterization, with a 
tool called “the fire drill”. The writing says about the disease, “There is no treatment”. 
The origin of the word cancer is credited to the Greek physician Hippocrates (460-
370 B.C.), the "Father of Medicine." Hippocrates used the terms carcinos and carcinoma to 
describe non-ulcer forming and ulcer-forming tumors. In Greek these words refer to a crab, 
most likely applied to the disease because the finger-like spreading projections from a 
cancer called to mind the shape of a crab. Carcinoma is the most common type of cancer. 
According to the doctrines of the Greek physician Caudius Galen (130-200 AD), 
whose works on physiology and anatomy dominated medical thought until the Middle 
Ages, melancholia was the chief factor in the development of breast cancer. Special diets 
were the recommended treatment. However, other treatments included exorcism and the 
use of topical applications which were seldom preferred by patients.  
During the Renaissance, Andreas Vesalius recommended mastectomy as well as 
ligatures (sutures) to control the bleeding rather than cautery. Recognition that breast 
cancer could and did spread to the regional auxiliary nodes was first recognized by the 
physician LeDran (1685-1770). Dr. LeDran was likely the first to associate poor prognosis 
with the spread of breast cancer to the lymph nodes. 
The famous Scottish surgeon John Hunter (1728-1793) suggested that some 
cancers might be cured by surgery and described how the surgeon might decide which 
cancers to operate on. If the tumor had not invaded nearby tissue and was “moveable”, he 
said, “There is no impropriety in removing it”. 
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During the mid 1800’s, surgeons first began to keep detailed records of breast 
cancer. Those statistics indicate that even those treated by mastectomy had a high rate of 
recurrence within eight years—especially when the glands or lymph nodes were affected. 
Nevertheless, the common treatment was to remove the breast and the surrounding glands 
in an effort to stave off any further tumor development. 
In 1894 William Roentgen discovered X-rays. This paramount discovery shed light 
on the detection of many diseases as well as breast cancer. Some years later, in 1913, 
Albert Solomon, a pathologist in berlin, produced images of 3,000 gross mastectomy 
specimens. He observed black spots at the centers of breast carcinomas 
(microcalcifications).  
Between the 1930’s and the 1950’s treatment and detection improvements were 
noticeable. This was the time when Stafford Warren (Rochester memorial Hospital, New 
York) developed a stereoscopic system for tumor identification. Also, doctors started 
classifying the stage and progression of breast cancer. In 1949 Raul Leborgne (Uruguay) 
emphasized breast compression for identification of calcifications. In 1940s-1950s breast 
self-examinations were advocated. 
In 1960 Dr. Robert Egan (Houston) adapted high-resolution industrial film for 
mammography, allowing simple and reproducible mammograms with improved image 
detail. And in 1963 the first randomized controlled trial of screening by the Health 
Insurance Plan of New York found that mammography reduced the 5-year breast cancer 
mortality rate by 30 percent. Major improvements in mammography equipment, such as 
reduced radiation dosage, digital imaging, and computer-aided diagnosis, improved 
detection of breast cancer.  
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Breast Cancer Risk Factors 
Every woman is at risk for developing breast cancer. Several relatively strong risk 
factors for breast cancer that affect large proportions of the general population have been 
known for some time. However, the vast majority of breast cancer cases occur in women 
who have no identifiable risk factors other than their gender (9).  
The “established” risk factors for breast cancer are female gender, age, previous 
breast cancer, benign breast disease, hereditary factors (family history of breast cancer), 
early age at menarche, late age at menopause, late age at first full-term pregnancy, 
postmenopausal obesity, low physical activity, race/ethnicity and high-dose exposure to 
ionizing radiation early in life. 
The “speculated” risk factors for breast cancer include never having been pregnant, 
having only one pregnancy rather than many, not breast feeding after pregnancy, use of 
postmenopausal estrogen replacement therapy or postmenopausal hormone 
(estrogen/progestin) replacement therapy, use of oral contraceptives, certain specific 
dietary practices (high intake of fat and low intakes of fiber, fruits, and vegetables, low 
intake of phytoestrogens), alcohol consumption, tobacco smoking, and abortion.  
Although men can and do develop breast cancer, the disease is 100 times more 
likely to occur in a woman than in a man (10). Women are at a higher risk of breast cancer 
because they have much more breast tissue than men do. Also, estrogen promotes the 
development of breast cancer. 
The risk of breast cancer is higher in middle-aged and elderly women than in young 
women (10; 11). This risk increases as a woman ages, rising sharply after the age of 40.  In 
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the United States, more than three-fourths of all breast cancers occur in women aged 50 or 
older. 
A woman who has previously had breast cancer has a three- to four-fold increased 
risk of developing a new cancer in the other breast. Women who have had benign breast 
problems are also at increased risk but to a lesser extent (12; 13). The risk of breast cancer 
is higher among women who have a close blood relative (mother, sister, or daughter) who 
have had the disease. The increase in risk is especially high if the relative developed breast 
cancer before the age of 50 or in both breasts (14). However, most women who get breast 
cancer (approximately 80 percent) have no such family history of the disease (15). The 
effect of family history on breast cancer risk is believed to be due primarily to genetic 
factors. As much as 5–10 percent of all breast cancer cases are attributable to specific 
inherited single-gene mutations, and many other cases have some genetic component. The 
evidence from individual families in which breast cancer occurs very frequently and from 
large epidemiological studies has shown that some women have a familial predisposition 
to breast cancer. The evidence includes the pedigree of Broca’s family (16). He was a 
famous French surgeon (1824-1880), and in his family tree (comprising over five 
generations) 10 out of 24 women died of breast cancer.  
Epidemiological studies have shown that in women with a family history of breast 
cancer, the risk of breast cancer is increased two- to threefold. Studies have also shown 
that there are families in which breast cancer risk is inherited in an autosomal-dominant 
fashion (‘hereditary breast cancer’). Recently, it has been shown that germline mutations in 
the BRCA1 and BRCA2 genes account for a large proportion of cases of hereditary breast 
cancer (17). Histopathological findings and careful autopsy examinations have played a 
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major role in the recognition of many familial cancer syndromes (18). In addition to 
mutations in the BRCA1 and BRCA2 genes, there are as yet unidentified genetic defects 
that predispose to breast cancer development (19), and additional studies may help in 
identifying these genes in the future.  
Women who reach menarche at a relatively early age (12 or younger) and those 
who reach menopause at a relatively late age (55 or older) are slightly more likely than 
other women to develop breast cancer (13). These relationships are believed to be mediated 
through estrogen production (20). During the reproductive years, a woman’s body 
produces high levels of estrogen. Women who start to menstruate at an early age and/or 
reach menopause at a late age are exposed to high levels of estrogen for more years than 
are women who have a late menarche or early menopause. 
Age at first pregnancy is another aspect of reproductive history that is associated 
with breast cancer risk. Women who have their first full-term pregnancy at a relatively 
early age have a lower risk of breast cancer than those who never have children or those 
who have their first child relatively late in life (13). The biologic basis for this relationship 
is not entirely clear. 
Obesity has been consistently associated with an increased risk of breast cancer 
among postmenopausal women (21; 22). This relationship may be mediated again by 
estrogen production. Fat cells produce some estrogen and obese postmenopausal women, 
therefore, tend to have higher blood estrogen levels than lean women. 
     Studies have consistently shown that the risk of breast cancer is lower among physically 
active premenopausal women than among sedentary women (23; 24). Physical activity 
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during adolescence may be especially protective, and the effect of physical activity may be 
strongest among women who have at least one full-term pregnancy. 
Studies of racial/ethnic characteristics of breast cancer reveal that non-Hispanic 
white, Hawaiian, and black women have the highest levels of breast cancer risk. Other 
Asian/Pacific Islander groups and Hispanic women have lower levels of risk. Some of the 
lowest levels of risk occur among Korean and Vietnamese women (25). 
Women who were exposed to high doses of radiation, especially during 
adolescence, have an increased risk of breast cancer. This association has been observed 
both among atomic bomb survivors and among women who received high-dose radiation 
for medical purposes (26; 27). 
Parity (having children) and the age of the woman at the birth of her first offspring 
are other endogenous hormonal factors that influence breast cancer. Women who have 
never had children (nulliparous) are at greater risk for the development of breast cancer 
than women who have had children (parous). There is also consistent evidence that first 
pregnancy completed before age 30-35 lowers risk of breast cancer, and that first full-term 
pregnancy after age 30-35 raises risk. More limited evidence suggests that women who 
have many pregnancies may be less likely to develop breast cancer than those who have 
only one pregnancy (13). 
Some studies have shown that women who breast-feed their babies may be less 
likely to develop breast cancer than those who have children but do not breast-feed (28). 
Other studies, however, indicate that there may be little or no relationship between breast 
feeding and breast cancer risk. If breast-feeding does protect against breast cancer, it may 
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do so by delaying the resumption of ovulation (with its accompanying high estrogen 
levels) after pregnancy. 
The long-term (more than five years) use of postmenopausal estrogen therapy 
(ERT) or combined estrogen/progestin hormone replacement therapy (HRT) may be 
associated with an increase in breast cancer risk (29).  
The associations between the use of oral contraceptives and breast cancer have 
been studied. Many studies attempting to link oral contraceptives with increased breast 
cancer have been inconclusive (30). But these studies have shown that oral contraceptives 
do not have a large effect on breast cancer risk. Whether they have a small effect on risk is 
less clear. 
A possible relationship between breast cancer and diet has been suggested due to 
the variation of breast cancer in societies with different national diets (the high rates in 
Western industrialized nations and the low rates in Asia, Latin America, and Africa). A 
comparison of vegetarian versus meat-eating women produced inconclusive results. No 
relation between breast cancer risk and total fat, saturated fat, or cholesterol was found. 
Some of the effects that were once attributed to dietary fat intake were probably due to 
obesity (which is often linked with high fat intake) rather than to fat intake per se. And the 
effects of fiber, fruits, and vegetables now appear to be small, at best. Diets high in fruits 
and vegetables and low in fat and calories are healthful for many reasons, and they may 
indirectly reduce the risk of breast cancer by helping to prevent obesity. 
Plant substances called isoflavones (sometimes referred to as phytoestrogens) are 
most commonly found in soy products. It has been speculated that these substances may be 
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protective against breast cancer (31). They appear to have effects similar to those of 
estrogen in some tissues while antagonizing the effects of estrogen in other tissues.  
A positive, but modest association between alcohol use and breast cancer risk is 
seen in most studies (32; 33). There is also some evidence that cigarette smoking may be 
associated with a small increase in breast cancer risk. However, epidemiological studies 
have variably shown positive, inverse, or null associations (34). Among women who have 
already been diagnosed with breast cancer, smoking may be associated with an increased 
risk that the cancer will progress more rapidly. In some studies, premature termination of 
pregnancy appears to increase breast cancer risk (35). In incomplete pregnancy, the breast 
is exposed only to the high estrogen levels of early pregnancy and thus may be responsible 
for the increased risk seen in these women. However, some other studies found no 
association between abortions and increased risk of breast cancer (36). 
Stages of Breast Cancer 
The staging systems currently in use for breast cancer are based on the clinical size 
and extent of invasion of the primary tumor (T), the clinical absence or presence of 
palpable axillary lymph nodes and evidence of their local invasion (N), together with the 
clinical and imaging evidence of distant metastases (M). This is then translated into the 
TNM classification which has been subdivided into Stage 0 called carcinoma in situ 
(lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) and four broad 
categories by the Union Internationale Centre Cancer (UICC), which are the following. 
Stage I – early stage breast cancer where the tumor is less than 2 cm across and 
hasn't spread beyond the breast. 
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Stage II – early stage breast cancer where the tumor is either less than 2 cm across 
and has spread to the lymph nodes under the arm; or the tumor is between 2 and 5 cm (with 
or without spread to the lymph nodes under the arm); or the tumor is greater than 5 cm and 
hasn't spread outside the breast. 
Stage III – locally advanced breast cancer where the tumor is greater than 5 cm 
across and has spread to the lymph nodes under the arm; or the cancer is extensive in the 
underarm lymph nodes; or the cancer has spread to lymph nodes near the breastbone or to 
other tissues near the breast. 
Stage IV – metastatic breast cancer where the cancer has spread outside the breast 
to other organs in the body. 
The Past and the Future of Breast Cancer Detection 
Increased breast cancer awareness with breast self-examinations and major 
improvements in routine breast cancer screening had a paramount effect on early detection 
of breast cancer. Improvements in  conventional mammography (an x-ray technique to 
visualize the internal structure of the breast) such as the low radiation dosage, enhanced 
image quality, development of statistical techniques for computer-assisted interpretation of 
images, long-distance, electronic image transmission technologies (telemammography 
/teleradiology) for clinical consultations, and improved image-guided techniques to assist 
with breast biopsies (the removal of cells or tissues for examination under a microscope) 
continue to lower the morbidity and mortality of breast cancer. The support of research on 
technologies that do not use x-rays and are not used for routine breast cancer screening, 
such as magnetic resonance imaging (MRI), ultrasound, and breast-specific positron 
emission tomography (PET) may play a considerable role in further improvements of 
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breast cancer early detection. In most cases, the earlier breast cancer is detected, the better 
the survival rate. Today mammography is the best available method to detect breast cancer 
in its earliest, most treatable stage - an average of 1.7 years before the woman can feel the 
lump. Generally, treatment is most effective before the disease spreads. When breast 
cancer is diagnosed at a local stage, the 5-year survival rate is greater than 90%. This rate 
decreases to less than 50% when the disease has spread to the lymph nodes and less than 
20% when it has spread to distant organ sites.  
Despite recent progress in early detection and surgical therapy, the mortality due to 
breast cancer has changed little over the past decades, primarily because the occult 
dissemination of cancer cells can occur at an early stage of carcinogenesis. Occult 
dissemination of tumor cells in patients with operable cancer can subsequently lead to 
formation of metastasis, yet it is usually missed by conventional tumor staging. The 
success of routine mammography screening for breast cancer is that it involves 
increasingly more patients with small primary tumors formerly thought to have an overall 
excellent prognosis. Yet, only approximately two thirds of these patients actually have this 
favorable prognosis, while the remaining third develops metastatic disease. Thus, there is 
emerging evidence that tumor cells can disseminate into secondary organs at an earlier 
stage of primary tumor development than appreciated by current risk classifications. There 
are several challenges that must be addressed in an effort to continue to lower the mortality 
associated with this disease.  
Molecular oncology is currently one of the most promising fields, which may 
address the major problems with early detection and accurate staging of women with breast 
cancer. The advent of highly sensitive, molecular techniques, such as the polymerase chain 
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reaction (PCR), enables the detection of circulating tumor cells and small metastasis at the 
molecular level. PCR-based assays are used for the detection of tumor cells in lymph 
nodes, resection margins, bone marrow and blood. Methods to detect metastatic disease 
and circulating tumor cells at a molecular level are of two types: those that detect somatic 
events such as point mutations or chromosomal rearrangements, and those that detect 
expression of tumor specific mRNAs. Both methods have been applied for the detection of 
many different tumor types (37). The main limitation of the first method is that not all 
tumors contain mutations suitable for PCR amplification. For the second method to work, 
the molecular marker must be transcriptionally elevated in malignant cells and not in the 
surrounding cells or tissue.  
Gene amplification/overexpression is a common event in the progression of human 
cancers, and amplified genes have been shown to serve as molecular markers and have 
diagnostic, prognostic and therapeutic relevance. Currently, molecular markers offer the 
unique opportunity to identify occult metastases in early stage cancer patients not 
otherwise detected with conventional staging techniques. The completion of the human 
genome as well as an enormous amount of information on the transcriptional activities in 
cancer cells enable the selection of specific markers for the detection of cancer cells. The 
ideal prognostic marker is one that clearly delineates a particular prognostic group, is 
100% specific, highly sensitive, inexpensive and easy to perform on a small quantity of 
fresh or fixed tissue. No such marker exists but a number of potential prognostic markers 
have been extensively investigated. Multiple proteins have been found to be specifically 
overexpressed in certain types of tumors (i.e. Her2neu, PSA, p53, pRB, melanoma 
antigens, etc.). Detection and quantification of potential tumor markers using sensitive 
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molecular methods could assist in the early diagnosis of cancer disease as well as in the 
efficacy of anti-cancer therapy. The clinical application of molecular markers in the 
diagnosis, staging, and management of breast cancer continues to expand. The molecular 
detection of circulating tumor cells and micrometastases may help develop new prognostic 
markers. Extensive work by various groups has been done on minimal residual disease 
(MRD) detection in blood, bone marrow and lymph nodes in cancer patients with different 
types of cancer.  In the past 10 years, numerous investigators have attempted the detection 
of occult tumor cells in malignancies using the highly sensitive reverse transcriptase 
polymerase chain reaction (RT-PCR) technique. This is a particularly sensitive technique 
for the purpose of detecting occult breast cancer cells in the blood, bone marrow, and 
lymph nodes of breast cancer patients (38-40). It is simple, rapid, and semi-automatic, and 
is an alternative method to fluorescence in situ hybridization and immunochemistry. RT-
PCR has produced sensitivity levels of 1 tumor cell in 1,000,000 normal cells. It can detect 
micrometastases based on amplification of mRNA expressed exclusively in the cancer 
cells of interest or in significantly larger amounts in cancer versus non-cancer cells 
localized to the lymph node, other distant organs or circulating in the blood. RT-PCR may 
be a powerful tool for large randomized, prospective cooperative group trials and support 
future tumor-marker based biological and gene-therapy approaches. The labor intensive 
and time consuming pathological investigations can be minimized or substantially assisted 
using automated RT-PCR assays. These assays, in the vast majority, have been directed 
against tissue specific markers. In most studies on prostatic carcinoma, RT-PCR was able 
to specifically detect prostatic tissue specific markers in the peripheral blood, bone marrow 
and lymph nodes of patients with localized and metastatic disease. Melanoma related 
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transcripts were detected by RT-PCR in the peripheral blood, bone marrow and lymph 
nodes of patients with localized and advanced tumors. Many authors have shown a 
statistically significant correlation between RT-PCR positivity and a poorer outcome in 
both melanoma and prostatic carcinoma. In breast carcinoma, all markers that have been 
extensively tested were shown to be non-specific.  
The presence or absence of axillary lymph node metastasis is still the single most 
reliable predictor of the final outcome in breast cancer and the primary determinant for the 
use of systemic therapy in patients with newly diagnosed cancer confined to the breast. 
Although these patients are considered as potentially curable, a substantial number of them 
develop recurrent carcinoma and die of their disease in 5 to 10 years, including nearly 30% 
of patients with negative axillary lymph nodes (41). As mentioned earlier, occult 
dissemination of tumor cells in the patients with operable cancer can subsequently lead to 
formation of metastases, yet it is missed by conventional tumor staging with 
histopathology and immunohistochemistry in the lymph nodes. The blood and bone 
marrow are not currently routinely examined for tumor cells in women with breast cancer. 
However, it is likely, that if these sites were routinely assessed, tumor cells would be 
identified. Ultimately, knowledge of tumor cells’ presence in the blood or bone marrow 
may impact the survival of breast cancer patients via earlier detection and initiation of 
adjuvant therapy. A reliable RT-PCR assay has not been developed for breast cancer. The 
targeted tumor markers for detection by RT-PCR in breast cancer patients have not been 
identified as in melanoma. In addition, because of the extreme sensitivity of RT-PCR 
technique, an accepted cut-off value that defines tumor presence or absence has not been 
established. However, it is widely accepted that the detection of mRNA tumor markers and 
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well-defined experimental protocols can greatly improve the sensitivity, specificity, and 
reliability of the RT-PCR assay system.  
Breast tumors are composed of a heterogeneous collection of cells with differing 
levels of individual gene expression. Therefore, the predominant cell type or its metastasis 
may not express a particular marker (42; 43). Therefore, it is believed that multimarker 
approaches with a panel of tumor-specific mRNA markers may improve the sensitivity and 
specificity for the detection of tumor cells over single marker assays in breast cancer 
patients. Furthermore, tumors continuously evolve genetically over time in response to 
host pressures and treatment interventions, which suggests that single marker testing may 
not be able to effectively monitor cancer progression. Simultaneous detection of such 
markers by newly developed methodologies such as real-time quantitative RT-PCR will 
enable the accurate monitoring of the level of mRNA markers as well as the precise 
comparison to known internal mRNA standards.  
Lymph node metastatic involvement is arbitrarily subdivided into micro- and 
macrometastases, usually according to the size of the tumor deposits, with the cut-off point 
ranging from 0.2 to 2.0 mm (44; 45). Serial sectioning and immunohistochemistry 
appeared to increase the detection rate by 9-33%. A definite survival disadvantage was 
noted for patients with such occult metastases. The use of extensive serial sectioning and 
immunohistochemistry on all axillary lymph nodes is too expensive and labor-intensive to 
be practical. Sentinel lymph node (SLN) is the first lymph node in the axillary basin to 
receive metastases from the primary breast cancer if they have occurred. The concept of 
SLN was introduced by Cabanas (46). The SLN accurately predicts the pathology of the 
remaining axillary basin allowing a focused pathologic analysis of it (47). If the SLN does 
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not contain tumor, the chance of tumor in the remaining axillary lymph nodes is less than 
1%. Therefore, patients without tumor in the SLN can avoid unnecessary axillary lymph 
node dissections (ALND). A SLN biopsy in comparison to an ALND has significantly less 
morbidity in terms of lymphedema, numbness to the arm, and decreased range of motion. 
The assessment of the SLN at the time of initial diagnosis of breast cancer may improve 
upon the current staging molecular method - multiple mRNA marker RT-PCR analysis, 
which would identify the sub-group of patients with metastases in the SLN but thought to 
be free of disease by conventional pathologic examinations. Therefore, the analysis of 
micrometastatic cells opens a new avenue by which to assess the molecular determinants 
of both early tumor cell dissemination and subsequent outgrowth into overt metastases. 
Tumor cell detection in the bone marrow is being regarded increasingly as a 
clinically relevant prognostic factor for breast cancer. Many studies suggest that tumor-cell 
shedding already occurs during the early stages of breast cancer and have demonstrated a 
significant correlation between tumor cell detection in the bone marrow and decreased 
disease-free and overall survival (48-50). Studies have shown that breast cancer patients 
may harbor bone marrow metastases alone or in conjunction with axillary metastases. 
These studies suggest that the tumor status of the bone marrow may be a better prognostic 
indicator than the axillary lymph node status (51). Since the primary breast tumor can 
spread by both the lymphatic and hematogenous route, it is possible that patients may have 
metastases to the bone marrow and not the axillary lymph nodes.  It is now clear that bone 
marrow is one of the most prominent secondary organs to receive disseminated tumor cells 
and is an important determinant for micrometastatic organ involvement due to its ease of 
accessibility and normal physiological absence of epithelial cells. Bone marrow aspirates 
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can be easily obtained from breast cancer patients at the time of surgery. The technical 
feasibility and the potential prognostic significance of bone marrow metastases makes 
assessing this site for tumor spread clinically important. Therefore, the multiple-marker 
RT-PCR assays may be used to molecularly stage the bone marrow detecting 
micrometastases not identified with conventional pathology.  
          Increased accuracy in staging breast cancer patient disease and initiation of earlier 
therapeutic interventions unequivocally are beneficial consequences of technological 
advancements that identify high-risk patients early in their disease course. Blood testing 
provides a minimally invasive method to evaluate the presence of circulating tumor cells 
that may serve as indicators for assessing risk of recurrence. Current imaging techniques 
used to identify breast cancer metastases often require a significant tumor burden for 
detection. Furthermore, the procurement of sufficient tissue to confirm the diagnosis can 
be associated with significant morbidity and cost depending on the size and location of the 
lesion as mentioned previously. Therefore, the utility of detecting tumor cells in the blood 
potentially offers a practical, safe, and cost-effective alternative to traditional methods of 
diagnosing disease recurrence and/or systemic spreading. In prostate and colon cancer, 
prostate specific antigen (PSA) and carcinoembrionic antigen (CEA) which are measured 
in the blood have served as a tremendous tool in the management of these cancer types 
respectively. To date, well-characterized molecular tumor markers to detect occult breast 
cancer cells in the blood are limited. There is no breast cancer tumor marker that can be 
measured in the blood, used for screening, serve as prognostic indicator, measure response 
to therapy, or signal early recurrence of the disease. The advantage of tumor marker 
detection in the blood is that it can be serially measured throughout the course of the 
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disease, unlike lymph node and bone marrow biopsies. The development of a multiple-
marker RT-PCR assay to detect micrometastases in the blood would considerably improve 
staging at the time of diagnosis of breast cancer patients enabling the early institution of 
the therapy that could lead to improved survival in patients that have disease relapse. A 
reliable breast cancer tumor marker that could be measured in the blood would potentially 
detect the disease before it becomes clinically visible on screening mammography or 
palpable on clinical exam. The increased levels of the tumor marker could lead to more 
frequent monitoring, further testing of patients, or earlier biopsy of suspicious lesions seen 
on mammography. It could also be used for postoperative monitoring, for determining the 
response to chemotherapy, and for prolonged post-treatment monitoring. The development 
of a multiple-marker RT-PCR assay that would be able to detect micrometastases in the 
blood identifying circulating tumor markers would have the potential to be used in above 
mentioned situations.   
  New prognostic markers can be tested in this very efficient way. If the study proves 
successful, the markers can be adopted for routine use either alone or, more probably, in 
combination with standard clinical assessment. It is believed that a number of molecular 
markers will make the transition from the laboratory to the clinic over the coming decades 
with the ultimate benefit being better prognostication and therapy of breast cancer patients. 
Tumor Markers 
A tumor marker is defined as a substance present/overexpressed in or produced by 
a tumor (tumor-derived), or the host (tumor-associated), that can be used for differentiating 
neoplastic from normal tissue. Tumor markers are found in cells, tissues, and body fluids 
such as cerebrospinal fluid, serum, plasma, and milk. The ideal marker would be useful in 
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diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and 
serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and 
screening in general populations (52). Most (if not all) tumor markers do not fit the ideal 
profile. The reason for this can be the relative lack of sensitivity and specificity of the 
available tests. It should be noted, that virtually any protein or chemical has the potential to 
be a tumor marker.  As tumor cells grow and multiply, some of their substances increase in 
tumor tissues and/or leak into the bloodstream or other fluids. Depending upon the tumor 
marker, it can be measured in blood, urine, stool or tissue. Some widely used tumor 
markers include: AFP, Her2/Neu, beta-HCG, CA 19-9, CA 27.29 (CA 15-3), CA 125, 
CEA, and PSA. Some tumor markers are associated with many types of cancer; others, 
with as few as one. Some tumor markers are always elevated in specific cancers; most are 
less predictable. However, no tumor marker is specific for cancer and most are found in 
low levels in healthy persons, or can be associated with non-neoplastic diseases as well as 
cancer. Tumor markers have been categorized as enzymes, isoenzymes, hormones, specific 
cell membrane proteins, oncofetal and cell-specific antigens, carbohydrate epitopes, 
oncogene products, genetic changes, etc. There are only a handful of well-established 
tumor markers that are being used by physicians. Many other potential markers are still 
being researched. There are many studies now that are trying to find new genes involved in 
signaling molecules or proteins that “tell” cells to proliferate, invade or metastasize. 
• AFP and CEA: There are two common oncofetal antigens, alpha-fetoprotein 
(AFP) and carcinoembryonic antigen (CEA). The oncofetal antigens are so named because 
they are normally produced during embryonic development and decrease soon after birth. 
Cancer cells tend to dedifferentiate, or revert to a more immature tissue and begin to 
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produce fetal antigens again. Oncofetal antigens are very non-specific and expressed by a 
wide number of cancer types. However, they are used both to monitor a patient's progress 
and their response to treatment over time. CEA is a cell surface glycoprotein and it is a 
marker for colorectal, gastrointestinal, lung, and breast carcinomas (53). CEA is most 
useful in monitoring therapy (as declining levels correlate with tumor burden) and has 
utility in detecting recurrence of colorectal cancer. High CEA levels in breast cancer do not 
correlate with grade of tumor but are useful for monitoring therapy and detecting 
recurrence. AFP is a marker for hepatocellular and germ cell (nonseminoma) carcinoma. 
For hepatocellular carcinoma (HCC), the sensitivity of AFP is 98% and the specificity is 
65%, making it the most useful marker for HCC (54). 
• Cancer antigen (CA) 27.29 is elevated in breast carcinoma, ovarian and 
lung cancer, in normal pregnancy (1st trimester), benign breast disease, cirrhosis and 
hepatitis (55). For recurrent breast carcinoma, CA 27.29 has a sensitivity of ~57% and a 
specificity of ~87% (56). It lacks the required sensitivity and specificity for routine 
detection of breast cancer and does not discriminate patients with early carcinoma from 
those with benign breast disease. CA 27.29 is associated with the early detection of 
recurrent breast carcinoma. 
• HER-2/neu is an oncogene-encoded growth factor receptor (homologue of 
epidermal growth factor (EGF) receptor), also known as c-erbB-2. It is overexpressed in 
breast cancers as a result of HER 2 proto-oncogene amplification. It is measured in the 
tissue from a biopsy either by immunological assays of the protein or PCR. The presence 
of HER-2/neu is generally associated with a more aggressive growth and poorer prognosis 
for breast and ovarian cancer (57; 58). It can also help to determine treatment options, 
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predicting an enhanced survival benefit from the Her 2-targeted therapy (reviewed by 
Horton, 2002 (59), Herceptin (trastuzumab), a monoclonal antibody that can block the 
protein receptor and decrease cancer growth. It may also predict for resistance to some 
conventional therapies.  
• Prostate specific antigen (PSA)  is the most valuable tumor  marker  for  the 
diagnosisand management of prostate cancer in terms of high specificity and utility (60), 
but it is now widely accepted that PSA is also present in many nonprostatic sources (61). 
PSA is a kallikrein-like serine protease first described in seminal plasma (62) and later 
found in prostatic tissue (63) and to a minor extent in milk (64) and amnionic fluid (65). It 
is a product of epithelial cells of the prostate and is secreted into the seminal fluid. The 
measurement of circulating PSA levels combined with digital rectal exam is recommended 
annually for all men over age 50. In addition to its use in screening, PSA is frequently used 
to monitor treatment of prostate cancer. Other factors affect the PSA level besides cancer. 
Older men tend to have a higher PSA normally. Also men with benign prostatic 
hypertrophy (BPH) have higher levels.  
• Estrogen receptor  (ER)  and  progesterone receptor (PR):  In  both  pre- and 
postmenopausal women, levels of steroid receptors ER and PR can predict which women 
are likely to benefit from hormone treatment. Measurements of ER and PR are 
recommended to use in the diagnosis, prognosis, and treatment planning for women with 
breast cancer. ER gives an indication of responsiveness to therapy. Tissue from a biopsy is 
used to measure the estrogen receptor. Most breast cancers in post-menopausal women are 
ER-positive, meaning that they require estrogen to grow. These ER positive breast cancers 
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are less aggressive than ER negative breast cancers, which are found generally in pre-
menopausal women. 
• P53 is a tumor suppressor gene that is  mutated or changed in  more  than 50 
percent of tumors. Studying p53 as a tumor marker helped researchers understand how 
tumors form, but measuring p53 levels in cancer patients has not been shown to predict 
differences in survival or quality of life. p53 was indicated as responsible for tamoxifen 
resistance in breast cancer suggesting that it can interfere in treatment response (66). 
• Cathepsin-D: High  levels  of  this  lysosomal  enzyme  may  indicate breast 
cancer. There is not enough information to recommend using cathepsin-D levels to make 
treatment decisions for patients with primary or metastatic breast cancer and especially to 
diagnose the disease but studies have shown its association with reduced disease-free and 
overall survival of breast cancer patients (67). 
Researchers continue working on specific molecular pathways involved in 
oncogenesis, tumor response, tumor progression, etc. to discover new molecular markers 
that can have a potential to be routinely used in medical practices of breast cancer. 
Laboratory techniques for the study of potential prognostic markers are rapidly developing 
at both the gene and protein level. Most techniques now allow the analysis of fresh or 
archival tissue. Some of the newly discovered markers are markers involved in cell cycle 
dysregulation (cyclin D1, p16INK4a, p14ARF), tumor invasiveness (VEGF, factor VIII 
related antigen, Cox-2), stromal-breast epithelium interactions (uPA and related proteins, 
E-cadherin, b1 integrin), etc. The documented list of potential breast cancer markers is 
expanding every day promising valuable discoveries of new markers and their use in 
clinical settings. 
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Microarrays 
Survival rates of breast cancer improved during the 1900’s. They are steadily 
increasing now probably as a result of earlier detection, better staging and improved 
treatment. It is thought that the recurrence and mortality rate was high due to poor early 
detection techniques. According to the American Cancer Society, mortality rates of breast 
cancer declined during the past decade with the largest decreases in younger women (68). 
These somewhat encouraging trends are primarily associated with improved screening 
techniques and the subsequent increase in diagnosis at an early stage when most cancers 
are more successfully treated. Unfortunately, most current therapies have limited efficacy 
in curing late-stage disease. Therefore, there continues to be a need to develop new 
approaches to diagnose cancer early in its clinical course, more efficiently treat its 
advanced stages, predict tumor’s response to therapy, and ultimately prevent cancer 
disease. A better understanding of how certain genes and their encoded proteins contribute 
to disease onset and tumor progression and how they influence the response of patients to 
therapies would be the only way to accomplish these goals. Our era of genetic, biological, 
and biochemical innovations gives prominent opportunities to address these questions 
uncovering molecular basis of cancer. DNA microarrays are one of the most promising and 
powerful technologies in this field becoming a major tool in biomedical area and reshaping 
molecular biology. Partial sequence data for thousands of genes have been generated due 
to the human genome project’s large-scale sequencing efforts (69; 70). The roles these 
genes play in various biological processes have yet to be elucidated. Defining gene 
expression profiles, i.e. comparing patterns of expression in different tissues and 
developmental stages, in normal and disease states, or in distinct in vitro conditions, is a 
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big step toward understanding these roles. RT-PCR, RNase protection assays, and 
Northern blot analysis can accomplish the above mentioned goals but these methods focus 
on only a few genes at a time. Using microarrays, a single hybridization experiment can 
generate an expression profile for hundreds-thousands of genes at once. The ability to 
analyse the expression level of thousands of genes in a single assay using DNA 
microarrays is transforming the way we do research (71; 72).  
The history of microarrays began 25 years ago with the Southern blot, which 
introduced the basic technique of anchoring nucleic acids to a solid support for analysis by 
hybridization. A DNA microarray is an orderly arrangement of known or unknown DNA 
samples attached to a solid support. Each DNA spot on the microarray is usually less than 
200 µM in diameter and an entire array typically contains thousands of spots. Many 
different design formats are possible (73). The samples attached to the solid support can be 
small oligonucleotides, cDNAs or genomic sequences. RNA is isolated from samples, 
reverse transcribed into cDNA and labeled. Then it is hybridized on a microarray and 
visualized by different techniques. 
The range of microarray technology applications is already enormous. While gene-
expression profiling is currently the dominant microarray application, microarrays are also 
increasingly being used in pharmacogenomics and molecular diagnostics research. The 
development of DNA microarrays (or “DNA chips”) in conjunction with human genome 
studies has promise to be used in development of a new taxonomy of cancer (74), 
including major insights into the genesis, progression, prognosis, and response to therapy 
on the basis of gene expression profiles.  Genome-wide expression profiling of disease 
states opens up a new window for discovery of molecular disease markers and clinical 
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monitoring of patients. Major refinements of the technology underlying DNA libraries, 
PCR, and hybridization have come together in the development of DNA microarrays.  
Currently available DNA microarrays are carefully designed to include genes that 
are of interest to researchers in breast cancer field. The use of DNA array techniques now 
allows for the simultaneous analysis of the mRNA expression levels of thousands of genes 
in mammary tumor cell lines and breast tumors to address different aspects concerning 
breast cancer. Using DNA microarrays researchers have attempted to identify clusters of 
genes not recognized by the currently available pathological techniques (75), to elucidate 
gene expression patterns and survival of breast cancer patients (76), to investigate DNA 
copy-number variations in breast cancer cell lines and tumors (77), to examine in vivo 
molecular events of breast cancer progression (78), to determine the global impact of gene 
copy number variation and reveal amplified novel genes (79), and predict breast cancer 
response to therapy (80). There are many other studies that used DNA microarrays to 
reveal questions of breast cancer phenomenon but it is impossible to refer to them all in 
this chapter. It is becoming clear that continued advancements in the comprehensive 
analysis of protein products in conjunction with already confined methods of measurement 
of mRNA expression may ultimately uncover the molecular basis of different cancers as 
well as breast cancer shedding light on uncountable questions about this problematic 
disease. 
Objectives of the Project 
The overall objective of this research was to contribute to improved diagnosis, 
prognosis, and outcome prediction of breast cancer disease through the use of molecular 
biological advances in the detection and quantification of multiple mRNA tumor markers. 
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Our hypothesis is that the use of well-developed real-time PCR technique will improve the 
detection of cancer cells. In addition, the use of real-time PCR in conjunction with 
molecular profiling of cancers through the use of DNA microarrays should ultimately 
provide a complete suite of molecular tools for the detection as well as characterization of 
breast metastatic tumors. 
The first goal of this project was to develop and evaluate RT-PCR assays based on 
fluorescent TaqMan methodology for the early detection and quantification of multiple 
mRNA tumor markers in the blood, bone marrow and lymph nodes of breast cancer 
patients. The use of automated, real-time PCR allows for the detection as well as 
quantification of the relative levels of multiple tumor mRNAs in comparison to invariable 
“housekeeping” mRNAs. This work is a direct continuation of previous work performed 
by Dr. Peter Bostick (81-84).  In initial studies, Dr. Bostick and colleagues showed the 
potential of detecting specific mRNA markers by conventional RT-PCR and Southern Blot 
analyses of breast cancer samples obtained from sentinel lymph nodes and blood. Initial 
markers included carcinoembryonic antigen (CEA), cytokeratin 19 (CK 19), CK 20, 
gastrointestinal tumor-associated antigen 733.2 (GA 733.2) and mucin-1 (MUC-1). CEA, 
CK 19, and MUC-1 have been efficiently detected by immunohistochemistry, however, 
detection of these mRNAs had no diagnostic value as mRNA markers for the detection of 
micrometastases by the RT-PCR assay, because they were expressed in relatively large 
amounts in both the blood and lymph nodes of individuals without cancer. Data about 
CK20 were inconclusive and additional experiments were warranted to establish whether 
CK20 could be used as a diagnostic mRNA tumor marker (81). The levels of expression of 
mRNA tumor markers C-Met, beta1 4GalNAc-T, and P97 were also compared. Whereas 
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all three tumor markers were expressed in 43% of histopathologically tumor-free sentinel 
nodes, the mRNA levels were significantly higher in patients with a family or prior history 
of breast cancer, infiltrating lobular carcinoma, estrogen receptor-negative tumor, or a 
higher Bloom-Richardson score. It was concluded that the multiple-marker RT-PCR and 
Southern blot assays improved the occult metastases detection in the sentinel node when 
compared to conventional hematoxylin and eosin staining and immunohistochemistry 
analysis. Expression of all 3 tumor mRNA markers in the sentinel node correlated with 
poor prognostic clinico-pathologic factors (82). In melanoma studies, Dr Bostick and 
colleagues compared detection of occult metastases in the sentinel node of melanoma 
patients by the hematoxylin and eosin staining and immunohistochemistry to detection of 
metastases by the multiple-mRNA marker RT-PCR assay. The levels of MAGE 3, MART-
1, and tyrosinase mRNA detected by RT-PCR were correlated with hematoxylin and eosin 
staining and immunohistochemistry assay results, standard prognostic factors, and disease-
free survival. Patients with histopathologically melanoma-free sentinel nodes who were 
multiple-mRNA marker positive were at increased risk of recurrence, while patients who 
were multiple-mRNA marker positive with histopathologically proven metastases in the 
sentinel node were at greatest risk of disease relapse, concluding that hematoxylin and 
eosin staining and immunohistochemistry underestimate the true incidence of melanoma 
metastases. Multiple-mRNA marker expression in the sentinel node more accurately 
reflected melanoma micrometastases and was also a more powerful predictor of disease 
relapse than the hematoxylin and eosin staining and immunohistochemistry alone (83). In 
another multiple-marker melanoma RT-PCR assay, the number of RT-PCR markers 
detected in blood was an independent prediction factor of disease recurrence significantly 
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predicting disease recurrence in 2, 3, and 4 years of follow-up (84). Molecular detection of 
circulating tumor cells, especially as multi-mRNA marker approach, has significant 
prognostic value in determining early disease recurrence and might be useful for stratifying 
patients for adjuvant therapy. Newer molecular methodologies such as real-time 
quantitative TaqMan RT-PCR and cDNA microarrays have been used in these feasibility 
studies for assessing the relative potential of diagnostic procedures for the detection of 
mRNA tumor markers in breast cancer patient samples. 
The following mRNA tumor markers, some of which were used also by Dr. 
Bostick, were selected for multi-marker TaqMan analysis: (I) MAGE 3 (melanoma antigen 
3); (II) HER2/NEU (human epidermal growth factor receptor 2); (III) MGB 1 
(mammoglobin 1); (IV) CK 20 (cytokeratin 20); (V) PSA (prostate specific antigen); and 
(VI) HPR (heparanase). The set of markers was selected for multi-marker assay on the 
basis of the available published data of expression and specificity of each marker in 
primary and metastatic tumors.  
MAGE (melanoma antigen) proteins are normal tissue antigens compartmentalized 
in testicular cells that play an important role in the early phase of spermatogenesis. 
Demethylation induces MAGE antigens in cells, suggesting that MAGE genes are 
important developmentally regulated genes under methylation control. Thus, genetic 
instability in cells causing loss of this methylating control could result in the preferential 
expression of MAGE genes in cancer cells. MAGE genes are preferentially expressed in 
many different cancers and detected at both the mRNA and protein levels (recognized by 
autologous cytolytic T lymphocytes (CTL). MAGE 3 gene is a member of MAGE gene 
family of tumor antigens expressed in many tumors of several types, such as melanoma 
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(85), ovarian carcinoma (86), hepatocellular carcinoma (87), head and neck squamous 
carcinoma (88), lung carcinoma (89) and breast carcinoma (90), but not in normal tissues 
except testes. 
The connection of HER 2 to breast cancer outcome was noted relatively long ago 
(91). As mentioned earlier, in breast cancer, HER 2 amplification/overexpression 
correlates with earlier relapse, shorter disease free-   and overall survival predicting for a 
poor clinical outcome (91; 57; 58). HER 2 is considered to be a clinically important 
molecule and testing for HER 2 abnormalities is already part of routine patient assessment 
in many parts of the world. Immunohistochemistry (IHC) and fluorescence in situ 
hybridization (FISH) are the most common HER 2 tests used and they guide breast cancer 
therapy. They show a high level of concordance, but there is currently no gold standard for 
HER 2 testing. The review by Dowsett et al (92) summarizes different assays used for 
HER 2 testing discussing their advantages and disadvantages. HER 2 testing approaches 
based on RT-PCR are very promising for the routine detection and quantification of this 
oncogene expression for primary and metastatic breast cancer diagnosis as well as for 
patient monitoring (93; 94). A well-developed and validated RT-PCR assay can be a major 
tool for HER 2 testing with defining cut-off values and other standards for the assay.  
Mammoglobin (MGB) is a member of the uteroglobin gene family. It is 
homologous to a family of secreted proteins that includes rat prostatic steroid-binding 
protein subunit C3, human Clara cell 10-kilodalton protein, and rabbit uteroglobin. 
Mammoglobin is a relatively recently discovered gene but it has already shown promise 
for breast cancer detection. Its expression is limited to the adult mammary epithelium and 
it is frequently upregulated in human breast cancer cell lines and primary (95; 96) as well 
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as metastatic breast cancer (97). Mammoglobin could be a potential serum marker for 
breast cancer diagnosis because it is secreted and is specific to breast tissue. 
Cytokeratines (CK), which comprise a multigene family of 20 related polypeptides, 
are constituents of the intermediate filaments of epithelial cells, in which they are 
expressed in various combinations depending on the epithelial type and the degree of 
differentiation. CK 20 is essentially confined to gastrointestinal epithelia, the urothelium 
and Merkel cells of epidermis. Sparse CK 20 positive epithelial cells have been noted in 
the thymus, bronchus, gall bladder, and prostate gland. CK 20 is expressed in endometrial 
(98) and hepatocellular carcinoma (99) tumors but not in the endometrium of patients with 
benign diseases or in the blood cells. 
As discussed earlier, PSA is a product of epithelial cells of the prostate secreted 
into seminal fluid. For some time it was believed that PSA was exclusively expressed in 
the prostate and that PSA in the circulation must be prostatic in origin. This has been the 
basis for the use of PSA as a tumor marker for prostate cancer and the detection of this 
cancer by measuring circulating PSA levels (100; 101). As mentioned before, later it 
became apparent that PSA is expressed in nonprostatic tissues. Also, since PSA was 
originally identified in the prostate, it has long been assumed that women, lacking a 
prostate, would have no circulating PSA. However, with the advent of highly sensitive 
assays it has become clear that there are low but detectable levels of PSA in the circulation 
of women (102). PSA expression has also been reported in a wide variety of tumors. It has 
been detected immunocytochemically in many primary and metastatic melanomas (103), in 
primary ovarian carcinoma (104), etc. Many of the studies on extraprostatic PSA were 
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inspired by reports that PSA could be detected in breast tumors and in serum of patients 
with breast cancer (105; 106).  
Heparanase (HPR) is an enzyme expressed by various cells such as platelets, 
leukocytes, endothelial cells and smooth muscle cells. It is an endoglycosidase (heparan 
sulfate-specific endo-beta-D-glucuronidase) that cleaves heparan sulfates (HS). Heparan 
sulfate proteoglycans (HSPGs) play a key role in the self-assembly and barrier properties 
of basement membranes and extracellular matrices. Hence, cleavage of heparan sulfate 
(HS) affects the integrity and functional state of tissues and thereby fundamental normal 
and pathological phenomena involving cell migration and response to changes in the 
extracellular microenvironment. The heparanase mRNA and protein are preferentially 
expressed in metastatic cell lines and human tumor tissues (107; 108). Enhanced 
heparanase expression correlates with increased chance of tumor metastases with tumor 
vascularity and poor prognosis of cancer patients (109-111). 
 The next objective was to focus on the use of low-density DNA arrays containing 
cell interaction genes for discovering additional tumor markers. This molecular detection 
technology would help to identify multiple tumor associated mRNAs overexpressed in 
breast cancer patients in a short time in contrast to time-consuming other different 
techniques. It was also anticipated that custom made microarrays could be made to include 
the newly discovered and promising markers. For the initial microarray feasibility studies 
it was decided to use Atlas Human Cell Interaction array from Clontech, a nylon cDNA 
array with 265 immobilized genes on it. Cell interaction molecules such as cell adhesion 
proteins, extracellular matrix proteins, proteases, etc. play key roles in mediating cell-cell, 
cell-tissue and cell-extracellular matrix interactions and are involved in the normal 
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processes of cell growth, division, differentiation, migration, as well as apoptosis. These 
genes are also important in many diseases and pathophysiological processes, including 
tumor invasion and metastasis, rheumatoid arthritis, cardiovascular disorders, wound 
healing, inflammation, and some central nervous diseases. Considerable research has been 
done to discover the particular role these proteins play in cancer diseases (112-116). The 
list of cell interaction molecules that could serve as potential tumor markers for early 
diagnosis of tumors and their metastases is continuing to expand. 
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MATERIALS AND METHODS 
Sample Acquisition, Storage, and Identification 
A limited number of tissue, bone marrow and blood samples were obtained via 
collaboration with surgeon oncologist Dr. Peter Bostick and the Baton Rouge General 
Hospital. Samples were stored at –80°C after arrival at LSU. RNA was isolated 
immediately upon arrival from a portion of the blood samples. The remaining blood 
samples were aliquoted into 2ml cryo vials and stored at –80°C. Large tissue samples were 
fragmented into smaller samples for ease of storage and application of RNA extraction 
procedures and stored at –80°C. Bone marrow samples were aliquoted into smaller 
samples within cryo tubes for future manipulations. The list of the samples stored in the 
GeneLab freeze, is shown in Table 1. All the samples were obtained from Dr. Bostick’s 
surgeries of confirmed or suspected breast cancer patients. 
 
Table 1. List of specimens received at LSU School of Veterinary Medicine  
Tissue samples Blood samples Bone marrow samples 
5062801Tln 
00716247Tln 
5061542Tln 
00657403Tbts 
00716247Tbtm 
0Tun 
5057331Tbtm  
00497241Tbtm 
05071355Tbtm 
05065155Tun 
5062801BD 
506322BD 
5061542BD 
657403BD 
05065155BD 
5057331BD 
8/02/00BD 
00408233BD 
05077954BD 
42578906BD 
5057331BMl 
713328BMl 
713328BMr 
313163BMr 
5057331BMr 
05062801BMl 
05062801BMr 
5061542BMr 
5056311BMl 
053145BMr 
5056311BMr 
5056242BMl 
053145BMl 
5056242BMr 
323496BMr 
323496BMl 
313163BMl 
5053504BMr 
05063173BMr 
05063173BMl 
42578906BMr 
42578906BMl 
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Samples are identified by a number assigned by the Baton Rouge General Hospital, 
which relates to each patient. An upper case T denotes tissue samples, ln denotes lymph 
node samples, un is for unidentified samples, bts is for breast tissue, btm is for breast 
tumor. An upper case BM denotes bone marrow samples, l is for left and r is for right 
aspirates. An upper case BD is for blood samples. For example, bone marrow sample 
number 713328 right is identified as 713328BMr.  
Table 2 includes the list of samples from patients confirmed to have metastatic 
breast cancer. 
 
Table 2. Samples of known origin 
 
 
Sample number           Histological type of cancer  Sample types  
 
 
    5056242  infiltrating ductal carcinoma     bone marrow    
 
    313163  infiltrating ductal carcinoma     bone marrow 
 
    5056311  infiltrating ductal carcinoma                   bone marrow 
 
    713328  intraductal and infiltrating carcinoma     bone marrow 
                            (mucinous type)          
    05057331  poorly differentiated mammary carcinoma     tissue, blood, bone marrow 
 
    5062801  infiltrating ductal carcinoma      tissue, blood, bone marrow 
       
    5061542  infiltrating ductal carcinoma      tissue, blood, bone marrow 
 
    506322  infiltrating ductal carcinoma            blood 
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RNA Extraction 
Total RNA was isolated from 0.65 cm cubes of tissue samples, from 0.25 ml blood 
and bone marrow samples using Absolutely RNA RT-PCR Miniprep Kit from Stratagene 
(La Jolla, California). The Absolutely RNA system simplifies the traditional guanidine 
thiocyanate method by using a silica-based matrix in a spin-cup format. Following lysis 
and homogenization of the clinical samples with Lysis Buffer-β-ME mixture, homogenates 
were passed through Prefilter Spin Cups by centrifugation at maximum speed to remove 
particulates and much of the DNA contamination. The filtrates were mixed with 70% 
ethanol, transferred to Fiber-Matrix Spin Cups (RNA binding spin cups) and spun. The 
bound RNA was washed with Law-Salt Wash Buffer and DNase treated by DNase solution 
(contained DNase Digestion buffer and RNase-Free DNase I). After multiple washes with 
High-Salt and Low-Salt Wash Buffers, RNA was eluted from the spin cups by Elution 
Buffer (a low ionic strength buffer). RNA in the Elution buffer was stored at –80°C for 
future use.  
RT-PCR Assays 
The Real-Time Quantitative One-Step RT-PCR TaqMan assays were performed on 
the Perkin Elmer ABI PRISM 7700 Sequence Detection System equipment (Applied 
Biosystems, Foster City, California), which provides product verification with the highest 
stringency and sensitivity permitting continuous automated reading of fluorescence 
intensities during PCR. Signal production is directly proportional to the hybridization of a 
fluorescent probe, which serves to authenticate the PCR product as well as quantify its 
relative amount in comparison to known internal controls (GAPDH, 18S, etc.). A total of 
six mRNA markers were tested. Those were: MAGE 3 (melanoma antigen E 3), HER 
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2/NEU (human epidermal growth factor receptor 2), MGB 1 (mammoglobin 1), CK 20 
(cytokeratin 20), PSA (prostate specific antigen), and HPR (heparanase). Dilutions of RNA 
samples from a cell line were used to construct standard curves for target genes and 
endogenous reference (GAPDH or 18S). RNA from negative breast cancer cell line 
Hs578Bst (American Type Culture Collection, Manassas, Virginia) was used as a 
calibrator. Primers and probes were chosen using Primer Express software (Applied 
Biosystems). Probes were labeled at the 5’ end with the reporter molecule 6-
carboxyfluorescein (FAM) and at the 3’ end with the quencher 6-carboxytetramethyl-
rhodamine (TAMRA) (Applied Biosystems) (Table 3).  
 
Table 3. Primer and probe sequences of each marker gene for real-time PCR amplification 
 
  Gene  GenBank Primer or        Sequence 
  accession Probe  
number 
 
  MAGE 3 U03735  Forward      GGTGAGGAGGCAAGGTTCTG 
    Reverse      TCTGCTCAAGAGGCATGATGA 
    Probe      ACTGGCAGATCTTCTCCTTCAGTGCTCCT 
 
  HER2/NEU X03363  Forward      AGTGTGCACCGGCACAGA  
    Reverse      TTGTGAGCGATGAGCACGTA 
    Probe      AGCCTGTCCTTCCTGCAGGATATCCAG 
 
  MGB1  AF015224 Forward      CAAGACAATCAATCCACAAGTGTCT 
    Reverse      AACACCTCAACATTGCTCAGAGTT 
    Probe      CTTCTTCAAGAGTTCATAGACGACAATGCCACTACA 
 
  CK 20  X73502  Forward      TGCGAAGTCAGATTAAGGATGCT 
    Reverse     CCACTGTTAGACGTATTCCTCTCTCA 
    Probe     CATACTTCAGTCTGAAGTCCTCAGCAGCCAGT 
 
  PSA  NM-001648 Forward     CATTGAACCAGAGGAGTTCTTGAC 
    Reverse     TCCAGCACACAGCATGAACTT 
    Probe     AACTTGCGCACACACGTCATTGGAA 
 
  HEP  AF144325 Forward      TCGTGGACCTGGACTTCTTCA 
    Reverse      ACAAGCCTCTGGCCAAGGTA 
    Probe      CCACGGACCCGCGGTTCCT 
 
 38
Amplifications of an endogenous control (GAPDH or 18S) were performed to 
standardize the amounts of sample RNAs added to reactions. Commercially available 
primers and probes for the housekeeping genes, GAPDH and 18S, were obtained from 
Applied Biosystems. The TaqMan One-Step RT-PCR Master Mix Reagents which 
combine the key components into a master mix designed for one-step RT-PCR were 
obtained from Applied Biosystems. The same universal thermal cycling parameters were 
used for all quantitative TaqMan assays. The reverse transcription step was carried out at 
48°C for 30 minutes. The polymerase (Amlitaq Gold) was activated at 95°C for 10 
minutes. Forty cycles of RT-PCR were done, each consisting of 95°C for 15 seconds and 
60°C for 1 minute.  
Data Analyses 
The levels of marker gene expression in tissue, blood and bone marrow samples, as 
well as in Hs578T positive cell line (American Type Culture Collection), were quantitated. 
Relative quantitation with data from the ABI PRISM 7700 Sequence Detection System 
(SDS) was performed using the SDS 1.7 Software (Applied Biosystems). The initial SDS 
software analysis of the acquired fluorescent data include normalization of the reporter dye 
signal to an internal passive reference, calculation of the ∆Rn and Ct values, and standard 
curve construction. Normalization was necessary to correct for fluorescent fluctuations due 
to changes in concentration or volume. Normalization was accomplished by dividing the 
emission intensity of the reporter dye by the emission intensity of the Passive Reference to 
obtain a ratio defined as the Rn (normalized reporter) for a given reaction tube. The 
Passive Reference was a dye included in the 10X TaqMan Buffer and did not participate in 
the 5’-nuclease assay. ∆Rn reliably indicated the magnitude of the signal generated by the 
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given set of PCR conditions. The value was calculated as the difference between the Rn+ 
value, the Rn of a reaction containing all components including the template, and the Rn- 
value, the Rn value of an unreacted sample, as for example that obtained from a reaction 
not containing template, a No Template Control. To ensure statistically high confidence 
levels, at least three No Template Controls per microplate were used. The threshold cycle 
or Ct value was the cycle at which a statistically significant increase in ∆Rn was first 
detected, in other words, the increase in signal associated with an exponential growth of 
PCR product.  
Relative quantitations were performed using the standard curve method. Below is a 
sample example of a standard curve for MAGE 3 and formulas used for calculations 
(Figure 2). 
 
 
Figure 2. MAGE 3 standard curve and quantitation formulas  
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The construction of standard curves was based on the linear relationship between 
the cycle threshold (Ct) and the log of concentration (ng) of a sample RNA. The input 
amount was calculated by using m and b values, then was normalized against the 
endogenous control (quantitation of an mRNA target normalized for differences in the 
amount of total RNA added to each reaction). Subsequently, it was calibrated using the 
Hs578Bst values (negative cell line from normal breast tissue).  
Microarrays 
Atlas Nylon Human Cell Interaction Arrays containing 265 genes encoding for 
cell-cell interaction molecules were purchased from BD Biosciences, Clontech (Palo Alto, 
California). The membranes also contained 9 housekeeping genes, such as ubiquitin C, 
tubulin alpha 1, cytoplasmic beta-actin, etc, and 3 negative controls (M13 mp18(+) strand 
DNA, lambda DNA, and pUC18 DNA). Atlas SpotLight Probe Labeling Kit (Clontech) 
was used for probe labeling and SpotLight Chemiluminescent Hybridization and Detection 
Kit (Clontech) was used for hybridization and detection procedures as specified by the 
manufacturer. Briefly, probe mixtures were synthesized and directly labeled by reverse 
transcribing the total RNA (extracted from 00716247Tln and 5062801Tln samples) using 
the cDNA synthesis (CDS) Primer Mix and the SpotLight Labeling Kit which contained a 
labeling mix with biotinylated dCTP. Labeled cDNAs were purified from unincorporated 
biotin-labeled nucleotides and small cDNA fragments using the Atlas Nucleospin 
Extraction Kit. Membranes were prehybridized at 42°C  for 2 hours, then they were 
hybridized with the biotin-labeled probes overnight at 42°C using the SpotLight 
Chemiluminescent Hybridization and Detection Kit. After high stringency washes 
hybridization patterns of probes were detected and signals were visualized both by 
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exposing the membranes to X-ray films and by scanning them using the AlphaEaseFC 
Imaging System equipment (FluorChem IS-8800, Alpha Innotech, San Leandro, 
California). 
Cloning and Spotting of Overexpressed Genes 
Three of the overexpressed genes from microarrays (EMMPRIN_extracellular 
matrix metalloproteinase inducer, DSH homolog 1-like; DVL1L1_dishevelled homolog 1-
like protein, and TIMP1_ tissue inhibitor of metalloproteinase 1) were cloned into the 
pcDNA2.1 vector (Invitrogen, Carlsbad, California) for E. coli propagation and confirmed 
by sequencing using T7 primer. The cloned fragments, about 500 base pairs each were 
amplified by PCR. 1µl of each PCR product and negative controls (H2O, λ DNA, and 
pUC19) were spotted in triplicate on nylon membranes (Zeta-Probe Membranes (Bio-Rad, 
Herculaes, California). Membranes were placed in UV Stratalinker 2400 equipment 
(Stratagene) to crosslink and immobilize the DNA samples. Membranes were 
prehybridized at 42°C for 2 hours, then they were hybridized with the biotin-labeled 
probes from 5062801Tln and 00716247Tln samples overnight at 42°C using the SpotLight 
Chemiluminescent Hybridization and Detection Kit. X-ray pictures were taken.    
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      RESULTS 
Development of TaqMan Assays for Selected mRNA Tumor Markers 
Detection and quantification of the relative expression levels of multiple tumor 
mRNAs requires high quality, contamination-free RNA with a satisfactory concentration 
for sensitive molecular methods such as RT-PCR. During the developmental stage of the 
breast cancer project, multiple methods and equipment were used to purify RNA until 
methodologies were developed to assure a high degree of reproducibility of real-time PCR 
results.  The best results were obtained when RNA was extracted using the Absolutely 
RNA RT-PCR Miniprep Kit (Stratagene, La Jolla, California) specifically optimized for 
RT-PCR incorporating effective on-column DNA removal specifically for RT-PCR 
applications. This system simplifies the traditional guanidine thiocyanate method by using 
a silica-based matrix in a spin-cup format. All the data presented here were derived from 
RNA samples purified with the above mentioned methodology (see Materials and 
Methods). 
TaqMan real-time quantitative RT-PCR assays were developed for six mRNA 
tumor markers: (I) MAGE 3 (melanoma antigen E 3); (II) HER2/NEU (human epidermal 
growth factor receptor 2); (III) MGB 1 (mammoglobin 1); (IV) CK 20 (cytokeratin 20); 
(V) PSA (prostate specific antigen); and (VI) HPR (heparanase). PCR primers and 
TaqMan probes were designed through the use of Primer Express software and empirical 
observations of the oligonucleotide sequences (see Materials and Methods).  In all 
instances the targeted nucleotide sequence was less than 200 bases long.  The expression 
levels of the marker genes relative to standard curves of cell lines were calculated, 
normalized against the endogenous control and calibrated to the negative breast cancer cell 
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line Hs578Bst as detailed in Materials and Methods. Figure 3 shows a typical real-time 
PCR amplification reaction as visualized and graphed by computer-assisted software in the 
Perkin Elmer ABI PRISM 7700 Sequence Detection System. Typically, robust 
amplifications of targets were obtained for both selected mRNA tumor markers as well as 
endogenous controls (GAPDH or 18S).  
 
 
 
 
 
 
 
 
Figure 3. Amplification plot of a real-time TaqMan RT-PCR experiment for MAGE 3 in 
bone marrow samples 
 
The tables below show the relative quantities for each of the six marker genes for 
the individual tissue, blood and bone marrow samples from the breast cancer patients 
(Tables 4; 5; 6; 7; 8; 9). 
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Table 4. Relative quantities of MAGE 3 marker gene expression in tissue, blood and bone 
marrow samples of breast cancer patients  
Bone Marrow 
Sample Name Calibrated to Hs578Bst Sample Name Calibrated to Hs578Bst
5062801Tln 2964 5057331BMl 73800
00716247Tln 19200 713328BMl 0.004
00657403Tbts 1163 713328BMr 2090
00716247Tbtm 103944 313163BMr 295
0Tun 4 5057331BMr 2400
5057331Tbtm 7010 05062801BMl 44200
05065155Tun 16218316 05062801BMr 1390000000
Hs578Bst 1 5061542BMr 27
Hs578T 152
5056311BMl 1680
053145BMr 2070000000000
Sample Name Calibrated to Hs578Bst
5056311BMr 22500
5062801BD 2
5056242BMl 5780
506322BD 0.2
053145BMl 4650000
5061542BD 28
5056242BMr 65300000
657403BD 119
323496BMl 1394808925
05065155BD 50
313163BMl 157610
5057331BD 130
Hs578Bst 1
8/02/00BD 4261 Hs578T 34827
Hs578Bst 1
Hs578T 0.03
Tissue
Blood
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Table 5. Relative quantities of HER2/NEU marker gene expression in tissue, blood and 
bone marrow samples of breast cancer patients  
Sample Name Calibrated to Hs578Bst Sample Name Calibrated to Hs578Bst
5062801Tln 308 713328BMl 894
00716247Tln 387 713328BMr 89
00657403Tbts 1 313163BMr 5
00716247Tbtm 62 5056311BMr 6
0Tun 0.4 053145BMl 8
5057331Tbtm 0.1 5056242BMr 1
05065155Tun 36 323496BMr 0.5
Hs578Bst 1 323496BMl 2
Hs578T 0.0002
313163BMl 4
Hs578Bst 1
Sample Name Calibrated to Hs578Bst Hs578T 0.0002
5062801BD 0.001
506322BD 0.02
5061542BD 0.0004
657403BD 0.06
05065155BD 0.01
5057331BD 0.009
8/02/00BD 14
00408233BD 4670
Hs578Bst 1
Hs578T 0.0002
Tissue
Blood 
Bone Marrow 
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Table 6. Relative quantities of MGB 1 marker gene expression in tissue, blood and bone 
marrow samples of breast cancer patients  
Bone Marrow 
Sample Name Calibrated to Hs578Bst Sample Name Calibrated to Hs578Bst
5062801Tln 16556 5057331BMl 4950582
5061542Tln 2332 713328BMl 105614
00657403Tbts 2350 713328BMr 66677
00716247Tbtm 9906 313163BMr 2231328
0Tun 7088 5057331BMr 45462
5057331Tbtm 4544 05062801BMl 467876522709
05065155Tun 5351 5061542BMr 4324264
Hs578Bst 1 5056311BMl 11400000000000
Hs578T 1066325
053145BMr 1427667908
5056311BMr 5717382771
Sample Name Calibrated to Hs578Bst
5056242BMl 26256465
5062801BD 33071
053145BMl 4759889
506322BD 4
5056242BMr 313464
5061542BD 2
323496BMr 80100000000000
657403BD 1039101
323496BMl 16416569953
05065155BD 5095152568
313163BMl 1411368915
5057331BD 46029599
5053504BMr 4733029432
8/02/00BD 0.04
05063173BMr 320991
Hs578Bst 1
Hs578T 1.7 05063173BMl 781037
Hs578Bst 1
Hs578T 1.7
Tissue
Blood 
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Table 7. Relative quantities of CK 20 marker gene expression in tissue, blood and bone 
marrow samples of breast cancer patients 
Tissue Bone Marrow 
Sample Name Calibrated to Hs578Bst Sample Name Calibrated to Hs578Bst
5062801Tln 4889029 5057331BMl 2167966
00716247Tln 97564 713328BMl 1428841363
5061542Tln 70451855 713328BMr 41930002922
00657403Tbts 13429158 313163BMr 71726552
00716247Tbtm 4214750 5057331BMr 626636
0Tun 33008 05062801BMl 6526575
5057331Tbtm 17200073 05062801BMr 70172857165
00497241Tbtm 1470000000000 5061542BMr 31445
05071355Tbtm 3182792 5056311BMl 1086430
05065155Tun 6601348 053145BMr 715024
Hs578Bst 1 5056311BMr 9705186
Hs578T 2038
053145BMl 6667135148
Blood 5056242BMr 765139883
Sample Name Calibrated to Hs578Bst
323496BMr 302212
5062801BD 367204206
323496BMl 62909073
506322BD 845000000000
313163BMl 5371481
657403BD 317000000000
5053504BMr 27545799
05065155BD 45964232658
05063173BMr 11527
5057331BD 24330876750
05063173BMl 38606
8/02/00BD 12550537
Hs578Bst 1
00408233BD 212000000000 Hs578T 2038
Hs578Bst 1
Hs578T 2038  
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Table 8. Relative quantities of PSA marker gene expression in tissue, blood and bone 
marrow samples of breast cancer patients 
Tissue Bone Marrow 
Sample Name Calibrated to Hs578Bst Sample Name Calibrated to Hs578Bst
5062801Tln 194413963 5057331BMl 50256
00716247Tln 10367891 713328BMl 15377518
5061542Tln 42253609027 713328BMr 9839563168
00657403Tbts 45996208 313163BMr 901129
00716247Tbtm 308727899 5057331BMr 91037
0Tun 2994075 05062801BMl 2090891
5057331Tbtm 9943595532 05062801BMr 3619288989
00497241Tbtm 203934000000000 5061542BMr 8884
05071355Tbtm 132404068 5056311BMl 40619
05065155Tun 549137203 053145BMr 8497
Hs578Bst 1 5056311BMr 142148
Hs578T 552304
323496BMr 2775
Blood 323496BMl 68251876
Sample Name Calibrated to Hs578Bst
313163BMl 2559204842
5062801BD 24515292365
5053504BMr 4099839
506322BD 2281920000000000
05063173BMr 29517
657403BD 50809400000000
05063173BMl 1858
05065155BD 324658000000000
Hs578Bst 1
5057331BD 570793000000000 Hs578T 552304
8/02/00BD 834879459
00408233BD 229069000000000
Hs578Bst 1
Hs578T 552304  
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Table 9. Relative quantities of HPR marker gene expression in tissue, blood and bone 
marrow samples of breast cancer patients 
Tissue Bone Marrow 
Sample Name Calibrated to Hs578Bst Sample Name Calibrated to Hs578Bst
00716247Tln 311249 5057331BMl 11870
5061542Tln 127561335 713328BMl 2
00657403Tbts 61928266888 713328BMr 118
00716247Tbtm 379353478 313163BMr 21
0Tun 94145598765 5057331BMr 1
5057331Tbtm 557200971 05062801BMl 308
05065155Tun 29940940539 05062801BMr 0.2
00497241Tbtm 3131 5061542BMr 12
05071355Tbtm 255363302 5056311BMl 67
42578906Ttm 9321463717 053145BMr 407
Hs578Bst 1 5056311BMr 152
Hs578T 29
5056242BMl 130
Blood 053145BMl 1524
Sample Name Calibrated to Hs578Bst
5056242BMr 0.3
5062801BD 1274055
323496BMr 1423
506322BD 56447
323496BMl 139909
657403BD 132809939
313163BMl 470
05065155BD 171114
5053504BMr 667198
5057331BD 406816
05063173BMr 41
8/02/00BD 735192
05063173BMl 74968
00408233BD 1525775
42578906BMr 17810643
05077954BD 224575511
42578906BMl 203346
42578906BD 3847460
Hs578Bst 1
Hs578Bst 1 Hs578T 37
Hs578T 13  
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Only three of the patients had all three types of samples (tissue, blood, and bone 
marrow) available. Table 10 shows the results of MAGE 3 relative expression for that 
three breast cancer patients with available tissue, blood, and bone marrow samples.  
 
Table 10. MAGE 3 expression in tissue, blood, and bone marrow samples of patients 
known to have breast cancer 
 
 
Sample number and types        Relative expression of MAGE 3 
 
      
     5057331   
     breast tumor tissue   high   
     blood    high  
     bone marrow (r)*   high   
     bone marrow (l)*   very high   
 
     5062801 
     lymph node tissue   high 
     blood    low 
     bone marrow (r)   very high 
     bone marrow (l)   very high   
   
     5061542 
     lymph node tissue **   - 
     blood    high     
     bone marrow (r)   high 
 
 
  
* r and l – right or left bone marrow aspirates 
** no available sample 
 
Selection of Additional mRNA Tumor Marker Genes through the Use of 
Micro-arrays Spotted With Genes Involved in Cell-cell Interactions 
A subset of the initial set of tumor markers represented cell surface expressed 
protein and glycoprotein antigens. Therefore, it was of interest to test additional cell 
surface expressed antigens as potential mRNA tumor markers.  For this purpose, 
commercially available microarrays containing genes coding for proteins involved in cell-
cell interactions were tested using labeled mRNA from specific tumor samples. Two tissue 
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samples, which had high relative expression levels of MAGE 3 and HER2/NEU genes 
were used in the microarray experiments with Atlas Nylon Human Cell Interaction Arrays 
containing 265 genes (Clontech, Inc). The arrays contained multiple housekeeping genes 
serving as internal controls, as well as genes serving as negative controls (see Materials 
and Methods). Biotin-labeled probes were prepared from 00716247Tln and 5062801Tln 
lymph node samples of two breast cancer patients. Figure 4A shows the photograph of the 
microarrays after hybridization using labeled cDNA probe obtained from the 0071624Tln 
tumor sample. Figure 4B shows the X-ray picture of the microarray hybridized with a 
probe made from the 5062801Tln sample. Both figures show a number of relatively 
overexpressed genes as dense dots pointed by arrows. 
A 
                             
 
Figure 4. Microarrays hybridized with lymph node samples. A. cDNA microarray was 
hybridized with biotin-labeled probe prepared from RNA of 0071624Tln sample. B. cDNA 
microarray was hybridized with biotin-labeled probe prepared from RNA of 5062801Tln 
sample. The arrows indicate the relatively overexpressed genes. The locations of 
overexpressed EMMPRIN, DVL1L1, and TIMP 1 genes are indicated by green, blue, and 
red arrows respectively (full names of the genes in Table 10) (Figure continued) 
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The top six of the highly overexpressed genes discovered as a result of these 
microarray experiments are listed in table 11. These six genes were found to be 
overexpressed in both microarray hybridization experiments. 
Table 11. The full and abbreviated names of some genes highly overexpressed on both 
microarrays  
GenBank 
Accession # 
Gene/protein name Gene/protein classification 
L20471 
 
basigin (BSG); leukocyte activation antigen M6; 
collagenase stimulatory factor; extracellular 
matrix metalloproteinase inducer (EMMPRIN); 
5F7; CD147 antigen 
Other Enzymes Involved in Protein 
Turnover 
Cell Surface Antigens 
U46461 dishevelled homolog 1-like protein (DSH 
homolog 1-like; DVL1L1) 
 
Other Intracellular Transducers, 
Effectors and Modulators 
M63928 
 
tumor necrosis factor receptor superfamily 
member 7 (TNFRSF7); CD27L antigen receptor 
 
Death Receptors 
Growth Factor & Chemokine Receptors 
Other Receptors (by Activities) 
Cell Surface Antigens 
D13866 alpha 1 catenin (CTNNA1); cadherin-associated 
protein 
 
Matrix Adhesion Receptors 
X03124 tissue inhibitor of metalloproteinase 1 (TIMP1); 
erythroid potentiating activity protein (EPA); 
collagenase inhibitor (CLGI) 
Protease Inhibitors 
M12807 CD4 antigen; T-cell surface glycoprotein 
T4/leu3 
Cell Surface Antigens 
 
Production of In-house Macroarrays for Selected Genes 
As part of these feasibility studies for assessing the relative potential of diagnostic 
procedures for the detection of mRNA tumor markers, it was essential to assess whether 
custom made macro and microarrays could be developed. For this purpose, three genes, 
which were highly overexpressed in both hybridization experiments were chosen for 
custom spotting on nylon membranes. A target nucleotide sequence of approximately 500 
bases from each gene was amplified using specific PCR primer sets, cloned into plasmid 
vectors for E. coli propagation and confirmed by DNA sequencing. Individual gene 
segments were re-amplified from their respective plasmids and spotted onto nylon 
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membranes (see Materials and Methods). The three genes selected for these experiments 
are shown on Table 12. 
Table 12. The full and abbreviated names of three overexpressed genes selected for 
spotting on nylon membranes 
 
Genes were spotted in triplicate onto nylon membranes and hybridized with biotin-
labeled probes prepared from 00716247Tln and 5062801Tln lymph node tumor samples. 
Figure 5 shows the hybridization pattern of the arrays containing the three genes as well as 
control DNA samples. The selected overexpressed genes appeared as triplets of dense-
stained dots. Negative controls did not show any hybridization signals. These experiments 
verified relative overexpression of EMMPRIN, DVL1L1, and TIMP 1 genes in tumor 
samples of breast cancer patients. 
 
 
        
GenBank 
Accession # 
Gene/protein name Gene/protein classification 
L20471 
 
basigin (BSG); leukocyte activation antigen M6; 
collagenase stimulatory factor; extracellular matrix 
metalloproteinase inducer (EMMPRIN); 5F7; 
CD147 antigen 
Other Enzymes Involved in 
Protein Turnover, 
Cell Surface Antigens 
U46461 dishevelled homolog 1-like protein (DSH homolog 
1-like; DVL1L1) 
 
Other Intracellular 
Transducers, Effectors and 
Modulators 
X03124 tissue inhibitor of metalloproteinase 1 (TIMP1); 
erythroid potentiating activity protein (EPA); 
collagenase inhibitor (CLGI) 
Protease Inhibitors 
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Figure 5. Hybridization pattern of three overexpressed genes (EMMPRIN, DVL1L1, and 
TIMP 1) and negative controls spotted on nylon membranes as triplets and hybridized with 
00716247Tln (left) and 5062801Tln (right) lymph node samples  
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      DISCUSSION AND CONCLUSIONS  
The overall goal of these investigations was to assess the potential of real-time 
quantitative RT-PCR based on fluorescent TaqMan methodology and microarray analyses 
as tools for the detection and quantification of multiple mRNA tumor markers of breast 
cancer. Previous work (81-84) showed the potential of detecting specific mRNA markers 
by RT-PCR and Southern Blot analyses of breast cancer and melanoma samples obtained 
from patients. It was concluded that the multiple-marker RT-PCR and Southern blot assays 
improve the occult metastases detection in patient samples when compared to conventional 
hematoxylin and eosin staining and immunohistochemistry analysis, which alone  
underestimate the true incidence of metastases.  
TaqMan Assays 
Newer molecular methodologies such as real-time TaqMan RT-PCR and cDNA 
microarrays have been used in these feasibility studies for assessing the relative potential 
of diagnostic procedures for the detection of mRNA tumor markers in breast cancer patient 
samples.  
To develop a sensitive detection assay for selected mRNA tumor markers in tissue, 
blood, and bone marrow samples of breast cancer patients, a variety of RNA extraction 
methods were attempted. The best method of RNA extraction included the use of a 
commercially available extraction kit (Absolutely RNA RT-PCR Miniprep Kit) 
specifically optimized for RT-PCR. The Absolutely RNA RT-PCR kit is stringently 
qualified for RT-PCR incorporating effective on-column DNA removal specifically for 
RT-PCR applications. The Absolutely RNA system simplifies the traditional guanidine 
thiocyanate method by using a silica-based matrix in a spin-cup format. RNA was 
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extracted from all the samples using the mentioned kit. Six mRNA tumor markers were 
selected and real-time quantitative RT-PCR TaqMan assays were developed and applied to 
detect them as well as quantify their relative expression levels in tissue, blood, and bone 
marrow samples. The selected markers were: (I) MAGE 3 (melanoma antigen E 3); (II) 
HER2/NEU (human epidermal growth factor receptor 2); (III) MGB 1 (mammoglobin 1), 
(IV) CK 20 (cytokeratin 20); (V) PSA (prostate specific antigen); (VI) HEP (heparanase). 
Among these six markers, MAGE 3 was the prevalent mRNA tumor marker and was 
reliably amplified from different samples of patients confirmed with breast cancer as well 
as from some blood samples. 18S (18S ribosomal RNA) and GAPDH (catalytic enzyme 
involved in glycolysis and called glyceraldehyde-3-phosphate dehydrogenase) internal 
standards were used as endogenous references (controls). Substantial problems were 
experienced obtaining reasonable Ct values for the endogenous control GAPDH. Multiple 
comparisons of experimental data suggested that 18S was a better endogenous control, thus 
GAPDH was used only for the initial runs that were testing the HER2/NEU marker and 
18S was used in TaqMan assays for the remaining five markers. 
Ideally, negative controls should be obtained from patients and the data from these 
negative samples should be used in quantitations. Because of substantial difficulties in 
obtaining appropriate negative controls, attempts were made to derive meaningful data by 
comparing clinical samples to a negative cell line derived from breast tissue. A similar cell 
line, obtained from breast tumor tissue of the same patient was also available as a positive 
control. Many of the mRNA markers could be efficiently amplified from tissue, bone 
marrow, and blood samples of patients known to suffer with metastatic breast cancer (see 
Materials and Methods, Table 2).  
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The results from TaqMan assays showed that some of the samples obtained from 
the same patient with breast cancer had a good correlation for high expressions of some 
markers. For example, MAGE 3 was amplified from tumor tissue, blood, and bone marrow 
of patient number 5057331 (see Results, Table 4). It had high expression values in all the 
three samples compared to negative cell line values. It was also overexpressed and was 
amplified from blood and bone marrow of patient number 5061542 (28- and 27-fold 
overexpression, respectively). Unfortunately, the lymph node tissue sample of this patient 
was depleted in earlier experiments, thus it couldn’t be tested for MAGE 3 gene 
expression. MGB1 had high expression values in lymph node and bone marrow of patient 
number 5061542 (2332- and 4324264-fold overexpression, respectively), although not in 
blood of the same patient (only 2-fold overexpression) (see Results, Table 6), which 
probably means that either there were no circulating tumor cells in the blood, or the marker 
MGB1 couldn’t be detected in circulating cancer cells. Table 10 shows the results of 
MAGE 3 relative expression for breast cancer patients with available tissue, blood and 
bone marrow samples. There were only these three patients for whom tissue, blood, and 
bone marrow samples were available. MAGE 3 was readily amplified from all of the three 
mentioned patient samples. 10-fold and higher overexpressions were considered high 
expressions, less than that were considered low. More than 10,000-fold overexpressions 
were considered as very high expressions (see also Table 4). Generally, MAGE 3 was 
overexpressed in all samples obtained from the three patients shown in Table 10, with the 
exception of one blood sample, which showed a low expression value for MAGE 3 leading 
to the conclusion that, most probably, there were no circulating cancer cells in this 
patient’s blood.   
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Overall, the results showed very high expression values for most of the markers. 
Some of these values were unreasonably high. For example, MAGE 3 was 207x 1010-fold 
overexpressed in right bone marrow aspirate of patient number 053145BMr (see Results, 
Table 4, Bone Marrow), MGB 1 was 801x1011-fold overexpressed in right bone marrow 
aspirate of patient number 323496 (see Results, Table 6, Bone Marrow), CK 20 was 
845x109 times overexpressed in blood sample of patient number 506322 and 147x1010 
times overexpressed in breast tumor sample of patient number 00497241 compared to 
negative cell line (see Results, Table 7), etc. These results indicate that calibrations to a 
negative cell line control produced artificially higher values of certain marker potentially 
because cell lines have very low amounts of these mRNA tumor markers. The absence of 
reliable negative samples from patients as well as the limited number of samples obtained 
were major problems, which prevented any statistical determination of the relative 
importance of the developed real-time PCR diagnostics. Real-time PCR may be a highly 
efficient diagnostic tool if positive and negative tissue samples can be obtained from the 
same patient, and if with positive blood and bone marrow samples obtained from breast 
cancer patients negative blood and bone marrow samples could be obtained from healthy 
individuals. Similarly, real-time PCR may be effectively applied to follow the disease 
progression and response to therapy of an individual patient.  
PCR methods have been shown to be superior in detecting minute amounts of 
tumor cells compared to other methods. The extreme sensitivity implies that false positive 
test results are likely to occur. The ultimate choice of molecular marker(s) and 
methodology to use in a clinical setting will be determined by its sensitivity and potential 
to discriminate between true micrometastases and background noise (117). The clinical 
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value of molecular detection of micrometastases will be detemined by its potential to 
increase prognostication of individual patients and by its predictive value of response to 
adjuvant treatment. For these purposes large trials are necessary in which the assay used to 
detect micrometastases gives unequivocal, reproducible results and is easy to use. For 
breast cancer, there is still a need for a cancer-specific marker which reliably can detect 
micrometastatic disease. Most probably a combination of carefully selected markers must 
be used to ensure a high detection rate. RT-PCR analysis is a particularly sensitive 
technique for the purpose of detecting occult breast cancer cells in the lymph nodes, blood, 
and bone marrow of breast cancer patients (38-40; 118). 
Microarrays  
The advent of microarray technology has revolutionized the molecular profiling of disease 
tissues and tumors. It is one of the most promising and powerful methodologies in 
molecular oncology. This newer technology was used to test additional molecules as 
potential mRNA tumor markers for breast cancer diagnostics. Cell interaction cDNA atlas 
nylon arrays were selected to pursue the goal of discovering additional markers, such as 
adhesion molecules, extracellular matrix proteins, etc. involved in cell to cell interactions. 
The basic assumption here was that cell surface proteins involved in cellular adhesion and 
cell-to-cell communication may be overexpressed in breast cancer samples. In this 
feasibility study, multiple overexpressed genes were identified from two lymph node 
samples of breast cancer patients as new potential mRNA tumor markers for diagnosis of 
breast cancer (see Results). Interestingly, genes for extracellular matrix metalloproteinase 
inducer (EMMPRIN), dishevelled homolog 1-like protein (DVL1L1), tissue inhibitor of 
metalloproteinase 1 (TIMP1), alpha 1 catenin (CTNNA1), tumor necrosis factor receptor 
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superfamily member 7 (TNFRSF7), and some other cell interaction molecules were highly 
overexpressed in the both lymph node samples of the breast cancer patients. Specifically, 
TIMP1 and EMMPRIN have been shown by others to be overexpressed in breast and some 
other cancers (119-123). There are many gaps in understanding the molecular basis of 
cancer metastasis formation, but it was shown that both EMMPRIN (inducer of MMPs) 
and TIMP-1 (inhibitor of MMPs) can be overexpressed in cancer patients playing crucial 
roles in cancer progression and predicting a poor prognosis. Invasion and metastasis of 
tumor cells involves the degradation of the basement membrane, caused by proteases 
derived from the tumor or adjacent normal cells or tumor-infiltrating immune cells. A class 
of proteases implicated in this process is the matrix metalloproteinases (MMPs), which are 
a family of zinc-dependent neutral endopeptidases. Aberrant MMP activity in tumor cells 
and surrounding stromal tissue is implicated in tumor progression, invasion, metastasis and 
angiogenesis. The activity of MMPs in the extracellular space is controlled by a family of 
specific inhibitors, the TIMPs. EMMPRIN is prominently displayed in human cancer 
tissue and plays an important role in cancer progression by increasing synthesis of MMPs 
(122; 123). EMMPRIN plays a role in tumor invasion, metastasis, and neoangiogenesis by 
stimulating extracellular matrix remodeling around tumor cell clusters, stroma, and blood 
vessels. The latest data suggest that dishevelled proteins organize dynamic subcellular 
signaling complexes functioning in signal transduction through Wnt pathways. Abnormal 
disheveled protein and Wnt signaling can cause a variety of diseases as well as cancer 
(reviewed by Wharton KA Jr. (124). 
From the initial experiments, three genes, which were highly overexpressed in both 
hybridization experiments, were selected for further investigations including custom 
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spotting on nylon membranes. These experiments revealed that diagnostic macro- and 
microarrays can be produced for the rapid screening of biological samples for the 
overexpression of mRNA tumor markers. These experiments utilized PCR-derived gene 
fragments of about 500 base pairs. Alternatively, multiple synthetic oligonucleotides 
representing different parts of each target gene can be spotted onto nitrocellulose or glass 
slides.  Rapid synthesis of oligonucleotides will enable the spotting of many gene targets 
onto arrays enhancing the potential for obtaining clinical relevant data. Finally, initial 
screening by microarrays can be followed by real-time PCR validation of individual 
mRNA results. 
The present investigations constituted feasibility studies for the development of 
reagents and protocols for the use of TaqMan and microarray assays. Overall, it was 
concluded that such assays can be easily designed and implemented for the screening of 
large number of clinical specimens.  TaqMan RT-PCR is an extremely sensitive technique. 
That’s why the presence of carefully selected controls, high purity RNA from samples, and 
other important parameters of TaqMan runs are of great importance. The TaqMan assays 
developed for this project can be used for the detection of mRNA tumor markers in various 
samples from breast cancer patients and probably will have more significant results when 
used for bigger sized samples with negative controls taken from same patients’ not 
diseased tissues or from healthy individuals. The set, rather than a single marker gene, may 
significantly decrease the likelihood of false positive results. 
Microarray experiments revealed that custom arrays can be easily produced 
incorporating many potential mRNA tumor markers.  Microarrays have a number of 
advantages over TaqMan assays, especially when many clinical samples are to be 
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screened. In addition, microarrays can incorporate multiple positive and negative controls 
as well as multiples of the same sample at different locations of the array to ensure 
reproducibility and statistical significance.  Ideally, initial screening of biological samples 
could be done by microarray analysis and individual positive samples could be confirmed 
by additional tests using TaqMan assays. 
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